No survival benefit from adding cetuximab to chemoradiotherapy in patients with stage III non-small cell lung cancer

The results of the RTOG 0617 phase III trial presented at the Presidential Symposium of the 15th World Conference on Lung Cancer (27-30 October 2013, Sydney, Australia) show that the high-dose radiotherapy with concurrent chemotherapy was not superior and may be worse than standard chemoradiotherapy in term of overall survival. The RTOG researchers also found that cetuximab provided no survival benefit in addition to standard chemoradiotherapy for patients with stage III non-small cell lung cancer. Read more here.